The new and contagious XEC COVID-19 variant is spreading rapidly in several countries. Will it cause a surge in the U.S.?

The monovalent XBB.1.5 COVID-19 vaccine is effective against XBB and JN lineage hospitalization; however, protection against the latter may be attenuated.

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...

While Australia's therapeutic goods regulator is evaluating two new vaccines targeting the JN.1 strain of COVID-19, the ...

For many, Novavax is #1 – the one and only COVID vaccine they would consider. This enthusiasm for Novavax isn’t new. As far back as 2022, news reports described a kind of Novavax fan club – a term ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...

The Workers Party government has failed to inform the population about the latest wave of the pandemic in Brazil, while ...

With the U.S. Food and Drug Administration and Centers for Disease Control and Prevention approval of new mRNA COVID-19 ...

Vaxxas today announced that it has initiated a multi-center Phase I clinical trial of a vaccine against pre-pandemic avian ...

The new "XEC" COVID-19 variant spreading rapidly in Europe has arrived in the US. What are the symptoms, will it cause a fall ...